These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678 [TBL] [Abstract][Full Text] [Related]
4. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184 [TBL] [Abstract][Full Text] [Related]
5. Differential gene expression analysis of ovarian cancer in a population isolate. Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569 [TBL] [Abstract][Full Text] [Related]
6. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191 [TBL] [Abstract][Full Text] [Related]
7. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Comin CE; Saieva C; Messerini L Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535 [TBL] [Abstract][Full Text] [Related]
9. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Welsh JB; Zarrinkar PP; Sapinoso LM; Kern SG; Behling CA; Monk BJ; Lockhart DJ; Burger RA; Hampton GM Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1176-81. PubMed ID: 11158614 [TBL] [Abstract][Full Text] [Related]
10. Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Turunen M; Talvensaari-Mattila A; Soini Y; Santala M Anticancer Res; 2009 Dec; 29(12):5185-9. PubMed ID: 20044634 [TBL] [Abstract][Full Text] [Related]
11. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413 [TBL] [Abstract][Full Text] [Related]
12. [Expression of EVEC in ovarian carcinoma and its biological significance]. Wang Q; Li XG; Zhang Y; Cao LQ; Deng ZH; Chen Y Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):676-80. PubMed ID: 21122382 [TBL] [Abstract][Full Text] [Related]
13. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351 [TBL] [Abstract][Full Text] [Related]
14. Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Miao Y; Cai B; Liu L; Yang Y; Wan X Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935 [TBL] [Abstract][Full Text] [Related]
15. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382 [TBL] [Abstract][Full Text] [Related]
18. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Dong Y; Kaushal A; Brattsand M; Nicklin J; Clements JA Clin Cancer Res; 2003 May; 9(5):1710-20. PubMed ID: 12738725 [TBL] [Abstract][Full Text] [Related]
19. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Grisaru D; Hauspy J; Prasad M; Albert M; Murphy KJ; Covens A; Macgregor PF; Rosen B Oncol Rep; 2007 Dec; 18(6):1347-56. PubMed ID: 17982616 [TBL] [Abstract][Full Text] [Related]
20. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]